Annual Report for FY 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma Limited filed its Annual Report for FY 2024-25 along with the notice for the 31st AGM scheduled on September 30, 2025. Total income rose sharply to Rs. 2,820.39 lacs from Rs. 1,110.12 lacs in FY 2023-24, a jump of about 154%. Despite the strong revenue growth, the company reported a net loss of Rs. 209.40 lacs (versus Rs. 575.05 lacs loss last year), and EPS remained negative at Rs. -5.60. Cash and cash equivalents were extremely low at just Rs. 9.03 lacs against outstanding term debt of Rs. 770.35 lacs. No dividend was declared. The auditor flagged two qualifications: a Rs. 40 lakh mutual fund investment held in the Managing Director's name (contravening Section 187 of the Companies Act) and Rs. 25 lakh in deposits accepted from a director's relative (contravening Sections 73-76 of the Act). The Board stated accounts were prepared on a going concern basis.
Revenue growth is a positive signal, but persistent losses, near-zero cash reserves against heavy debt, and auditor qualifications on regulatory non-compliance raise concerns about financial stability and governance for shareholders.